FDA Grants Priority Review to Garetosmab for Rare Bone Disorder Fibrodysplasia Ossificans Progressiva
The FDA has accepted for Priority Review Regeneron's biologics license application for garetosmab to treat adults with fibrodysplasia ossificans progressiva, with a target action date of August 2026.